Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis

Fig. 4

Parameters evaluated following the implementation of pembrolizumab therapeutic protocol. NO, L and H stand for no pembrolizumab, low-dose pembrolizumab and high-dose pembrolizumab, respectively. Cst, Crs and IC stand for static compliance, dynamic compliance and inspiratory capacity, respectively. Survival plot of mice included in the study. Two mice (low dose pembrolizumab: 1, high dose pembrolizumab: 1) were euthanized due to humane endpoints guidelines on day 12 (Panel A). All bleomycin-treated groups had statistically significant lower body weight than saline groups. Mice treated both with pembrolizumab and bleomycin had statistically significant higher weight compared to bleomycin-treated mice (Kruskal–Wallis test; bleomycin vs bleomycin and low dose pembrolizumab: p = 0.013, bleomycin vs bleomycin and high dose pembrolizumab: p = 0.004) (Panel B). Bleomycin-treated mice had statistically significant lower IC compared to mice treated with low dose pembrolizumab and bleomycin (Kruskal–Wallis test;p < 0.001) (Panel C). Bleomycin-treated mice had significantly lower Crs compared to both pembrolizumab groups (Kruskal–Wallis test; bleomycin vs bleomycin and low dose pembrolizumab: p < 0.001, bleomycin vs bleomycin and high dose pembrolizumab: p = 0.035) (Panel D). Bleomycin-treated mice had significantly lower Cst compared to mice treated with low dose pembrolizumab and bleomycin (Kruskal–Wallis test; p < 0.001). High dose pembrolizumab led to statistically significant lower Cst compared to low dose pembrolizumab (Kruskal–Wallis test; p = 0.025) (Panel E). BALF cellularity of all bleomycin-treated groups was significantly higher compared to the saline treated groups (Kruskal–Wallis test; p < 0.001 for every comparison) (Panel F). Total protein concentration in BALF was significantly higher in all bleomycin-treated groups compared to the saline treated groups (Kruskal–Wallis test; p < 0.001 for every comparison). There was a trend for higher total protein concentration in the ‘’high dose’’ compared to the ‘’low dose’’ pembrolizumab group (Kruskal–Wallis test; p = 0.07) (Panel G)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us